Journal of Laboratory and Clinical Medicine最新文献

{"title":"Restless legs syndrome: The CNS/iron connection","authors":"Mark W. Mahowald","doi":"10.1016/j.lab.2005.08.012","DOIUrl":"10.1016/j.lab.2005.08.012","url":null,"abstract":"","PeriodicalId":16273,"journal":{"name":"Journal of Laboratory and Clinical Medicine","volume":"147 2","pages":"Pages 56-57"},"PeriodicalIF":0.0,"publicationDate":"2006-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.lab.2005.08.012","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25839650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma","authors":"Amanda F. Baker ,&nbsp;Tomislav Dragovich ,&nbsp;Wendy R. Tate ,&nbsp;Ramesh K. Ramanathan ,&nbsp;Denise Roe ,&nbsp;Chiu-Hsieh Hsu ,&nbsp;D. Lynn Kirkpatrick ,&nbsp;Garth Powis","doi":"10.1016/j.lab.2005.09.001","DOIUrl":"10.1016/j.lab.2005.09.001","url":null,"abstract":"<div><p>Thioredoxin-1 (Trx-1) is a small redox protein that is overexpressed in many human tumors, where it is associated with aggressive tumor growth and decreased patient survival. Trx-1 is secreted by tumor cells and is present at increased levels in the plasma of cancer patients. PX-12 is an irreversible inhibitor of Trx-1 currently in clinical development as an antitumor agent. We have used SELDI-TOF mass spectroscopy to measure plasma Trx-1 from patients treated with PX-12 during a phase I study. Mean plasma Trx-1 levels at pretreatment were significantly elevated in the cancer patients at 182.0 ng/mL compared with 27.1 ng/mL in plasma from healthy volunteers. PX-12 treatment significantly lowered plasma Trx-1 in cancer patients having the highest plasma Trx-1 pretreatment levels. High-plasma vascular endothelial growth factor (VEGF) levels have been correlated to decreased patient survival. PX-12 treatment also significantly lowered plasma VEGF levels in cancer patients with high pretreatment VEGF levels. SELDI-TOF mass spectrometry identified seven additional plasma proteins whose levels decreased after PX-12 administration, one of which was identified as a truncated form of transthyretin. The results of this study suggest that the lowering of elevated levels of plasma Trx-1 in cancer patients may provide a surrogate for the inhibition of tumor Trx-1 by PX-12. Furthermore, PX-12 decreases plasma VEGF levels that may contribute to the antitumor activity of PX-12.</p></div>","PeriodicalId":16273,"journal":{"name":"Journal of Laboratory and Clinical Medicine","volume":"147 2","pages":"Pages 83-90"},"PeriodicalIF":0.0,"publicationDate":"2006-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.lab.2005.09.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25839654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of hepatitis B virus X protein on the development of liver cancer","authors":"Xiaodong Zhang ,&nbsp;Hang Zhang ,&nbsp;Lihong Ye","doi":"10.1016/j.lab.2005.10.003","DOIUrl":"10.1016/j.lab.2005.10.003","url":null,"abstract":"<div><p>Hepatitis B virus (HBV) infections play an important role in the development of cirrhosis and hepatocellular carcinoma (HCC). The pathogenesis of HBV-related HCC, however, has not been fully described. Evidence suggests that the HBV X protein (HBx) plays a crucial role in the pathogenesis of HCC. The high occurrence of anti-HBx antibody in the serum of HCC patients indicates that it could be a prognostic marker of HBV infection and HCC. HBx stimulates and influences signal transduction pathways within cells. HBx also binds to such protein targets as p53, proteasome subunits, and UV-damaged DNA binding proteins. It also interacts with the cyclic AMP-responsive element binding protein, ATF-2, NFκB, and basal transcription factors. HBx is primarily localized to the cytoplasm, where it interacts with and stimulates protein kinases, including protein kinase C, Janus kinase/STAT, IKK, PI-3-K, stress-activated protein kinase/Jun N-terminal kinase, and protein kinase B/Akt. It is also found in the mitochondrion, where it influences the Bcl-2 family. This review examines the role of HBx in the life cycle of HBV as well as the various signal transduction pathways involved in the pathogenesis of HBV-induced hepatocarcinogenesis.</p></div>","PeriodicalId":16273,"journal":{"name":"Journal of Laboratory and Clinical Medicine","volume":"147 2","pages":"Pages 58-66"},"PeriodicalIF":0.0,"publicationDate":"2006-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.lab.2005.10.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25839651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ferritin subunits in CSF are decreased in restless legs syndrome","authors":"Stacey L. Clardy ,&nbsp;Christopher J. Earley ,&nbsp;Richard P. Allen ,&nbsp;John L. Beard ,&nbsp;James R. Connor","doi":"10.1016/j.lab.2005.06.011","DOIUrl":"10.1016/j.lab.2005.06.011","url":null,"abstract":"<div><p>Restless legs syndrome (RLS) is a neurological disorder that may be related to iron misregulation at the level of the central nervous system. Evidence that iron is involved in RLS comes from magnetic resonance imaging data, autopsy studies, analyses of cerebrospinal fluid (CSF), and correlations of symptoms with serum ferritin. To further examine the possibility that brain iron status is insufficient in RLS, we determined ferritin levels in the CSF. Specifically, we differentiated between the H- and L-subunits of ferritin, because these peptides are expressed from different chromosomes and have different functions. We measured H- and L-ferritin subunit levels in control and RLS human CSF using immunoblot analysis and found that both H- and L-ferritin are significantly decreased in early but not late-onset RLS. Additionally, we quantified total protein in each CSF sample to establish that the decrease in ferritin subunits in RLS did not reflect a decrease in total protein in CSF. Furthermore, we used equal amounts of total CSF protein in the immunoblot analyses, in contrast to previously published studies that provided only volumetric data, to determine which approach was more accurate for quantifying the amount of ferritin relative to other proteins in CSF. Our results establish a protein standard in RLS, provide a comparative analysis of protein-controlled versus volumetric immunoblot techniques, and argue for a profound loss of iron storage capacity in the brain in RLS, specifically in the early onset RLS phenotype. These data suggest that CSF ferritin levels may provide a biomarker for assisting in the diagnosis of RLS.</p></div>","PeriodicalId":16273,"journal":{"name":"Journal of Laboratory and Clinical Medicine","volume":"147 2","pages":"Pages 67-73"},"PeriodicalIF":0.0,"publicationDate":"2006-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.lab.2005.06.011","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25839652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reduced podocyte expression of α3β1 integrins and podocyte depletion in patients with primary focal segmental glomerulosclerosis and chronic PAN-treated rats","authors":"Chien-An Chen ,&nbsp;Jyh-Chang Hwang ,&nbsp;Jinn-Yuh Guh ,&nbsp;Jer-Ming Chang ,&nbsp;Yung-Hsiung Lai ,&nbsp;Hung-Chun Chen","doi":"10.1016/j.lab.2005.08.011","DOIUrl":"10.1016/j.lab.2005.08.011","url":null,"abstract":"<div><p>Integrins attach cells to extracellular matrix (ECM) and mediate signals from ECM to cells or from cells to ECM. They regulate cell functions, including adhesion, migration, cell cycle regulation, and differentiation. Podocytes may detach from the glomerular basement membrane (GBM) and be excreted in the urine, and proteinuria is found in patients with primary focal segmental glomerulosclerosis (FSGS); both may be associated with loss of α3β1integrins. In this study, we have examined the podocyte number in patients with primary FSGS and normal controls, and the α3- and β1-integrin subunits expression of podocytes in patients with primary FSGS and chronic puromycin aminonucleoside (PAN)-treated rats by the morphometric, immunoperoxidase histochemical, and immunoelectron microscopic examination. We also measured their expression serially in rats that received repeated PAN injection. The results showed that the podocyte number was significantly decreased in patients with primary FSGS than in normal control (<em>P</em> &lt; 0.05). The immunostaining score showed that both α3- and β1-integrin subunits on podocytes in patients with primary FSGS were significantly lower than in normal controls (both <em>P</em> &lt; 0.01). The number of immuno-gold particles of α3- and β1-integrins at the effaced foot process area of patients with primary FSGS were also significantly decreased than that of normal controls (both <em>P</em> &lt; 0.05). The immunostaining score of both α3- and β1-integrin subunits was negatively correlated with the degree of glomerular sclerosing score and the amount of daily protein loss, and they were positively correlated with the number of podocytes. Chronic 12-week PAN-treated rats showed similar findings with decreased immunostaining expression and immuno-gold particles of α3-integrin on podocytes than in normal control (both <em>P</em> &lt; 0.05). The chronic PAN-treated rats also showed a trend toward gradually decreased immunostaining expression of α3-integrin subunit on podocyte during the progress from normal to FSGS state. These studies indicate that podocyte expression of α3- and β1-integrin subunits is significantly reduced in humans with primary FSGS and chronic PAN-treated rats, before the morphological changes of FSGS are observed. The decreased podocyte expression of α3β1 integrins is closely related with podocyte depletion, glomerular sclerosis, and daily protein loss in patients with primary FSGS.</p></div>","PeriodicalId":16273,"journal":{"name":"Journal of Laboratory and Clinical Medicine","volume":"147 2","pages":"Pages 74-82"},"PeriodicalIF":0.0,"publicationDate":"2006-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.lab.2005.08.011","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25839653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of angiotensin-converting enzyme 2 gene A/G polymorphism and elevated blood pressure in Chinese patients with metabolic syndrome","authors":"Jian Zhong,&nbsp;Zhengchen Yan,&nbsp;Daoyan Liu,&nbsp;Yinxing Ni,&nbsp;Zhigang Zhao,&nbsp;Shanjun Zhu,&nbsp;Martin Tepel,&nbsp;Zhiming Zhu","doi":"10.1016/j.lab.2005.10.001","DOIUrl":"10.1016/j.lab.2005.10.001","url":null,"abstract":"<div><p>To establish whether angiotensin-converting enzyme 2 (ACE2) gene A/G single nucleotide polymorphism is associated with hypertension in Chinese patients with metabolic syndrome. The study was conducted in 353 patients with metabolic syndrome. The alleles of the ACE2 A/G polymorphism, which is located on the X chromosome, were detected using polymerase chain reaction and subsequent cleavage by Alu I restriction endonuclease. G allele frequencies in patients with metabolic syndrome were 36.6% in female subjects and 43.4% in male subjects, respectively. Female patients with metabolic syndrome who carry the GG genotype had a significantly higher diastolic blood pressure compared with other genotypes. Multivariate logistic regression showed that female gender (<em>P</em> = 0.019) and carrying only the G allele (odds ratio 2.83 [95% CI 1.36 to 5.91]; <em>P</em> = 0.005) were significantly associated with increased diastolic blood pressure. It is concluded that the ACE2 A/G polymorphism is associated with hypertension in patients with metabolic syndrome.</p></div>","PeriodicalId":16273,"journal":{"name":"Journal of Laboratory and Clinical Medicine","volume":"147 2","pages":"Pages 91-95"},"PeriodicalIF":0.0,"publicationDate":"2006-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.lab.2005.10.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25839655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Information for readers","authors":"","doi":"10.1016/S0022-2143(06)00055-2","DOIUrl":"https://doi.org/10.1016/S0022-2143(06)00055-2","url":null,"abstract":"","PeriodicalId":16273,"journal":{"name":"Journal of Laboratory and Clinical Medicine","volume":"147 2","pages":"Page CO3"},"PeriodicalIF":0.0,"publicationDate":"2006-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0022-2143(06)00055-2","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"137323201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identifying type Vicenza von Willebrand disease","authors":"Alessandra Casonato ,&nbsp;Elena Pontara ,&nbsp;Francesca Sartorello ,&nbsp;Maria Grazia Cattini ,&nbsp;Lisa Gallinaro ,&nbsp;Antonella Bertomoro ,&nbsp;Antonio Rosato ,&nbsp;Roberto Padrini ,&nbsp;Antonio Pagnan","doi":"10.1016/j.lab.2005.10.002","DOIUrl":"10.1016/j.lab.2005.10.002","url":null,"abstract":"<div><p>Increased clearance of von Willebrand factor (VWF) is one of the main features of type Vicenza von Willebrand disease (VWD), a variant with plasma and platelet VWF level discrepancies and unusually large VWF multimers. Diagnosing type Vicenza VWD may not be easy, due to its heterogeneous phenotype. Here we describe the criteria we adopted to identify type Vicenza in a large group of VWD patients. Emphasizing the contribution of platelet VWF by comparison with plasma values, a first step involved selecting the candidate Vicenza patients on the basis of low or very low plasma VWF and a normal platelet VWF content. After excluding type 2A and 2B VWD patients, who may have normal platelet VWF, 18 candidates were found to meet our selection criteria. Genetic analysis revealed that 15 patients (from 5 unrelated families) were type Vicenza VWD and that all carried both G2220A and G3614A type Vicenza mutations barring one, who only had the G3614A mutation. All patients had a reduced VWF survival, and all but the patient with the G3614A mutation alone had ultralarge VWF multimers. Thus, low-plasma VWF associated with a normal platelet VWF content may be a first useful indicator for identifying type Vicenza VWD patients.</p></div>","PeriodicalId":16273,"journal":{"name":"Journal of Laboratory and Clinical Medicine","volume":"147 2","pages":"Pages 96-102"},"PeriodicalIF":0.0,"publicationDate":"2006-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.lab.2005.10.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25839656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"This month in J Lab Clin Med","authors":"Dale E. Hammerschmidt MD (Editor-in-Chief)","doi":"10.1016/j.lab.2006.01.003","DOIUrl":"https://doi.org/10.1016/j.lab.2006.01.003","url":null,"abstract":"","PeriodicalId":16273,"journal":{"name":"Journal of Laboratory and Clinical Medicine","volume":"147 2","pages":"Pages 53-55"},"PeriodicalIF":0.0,"publicationDate":"2006-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.lab.2006.01.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"137323189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"About the cover illustration","authors":"Dale E. Hammerschmidt MD (Editor-in-Chief)","doi":"10.1016/j.lab.2006.01.002","DOIUrl":"10.1016/j.lab.2006.01.002","url":null,"abstract":"","PeriodicalId":16273,"journal":{"name":"Journal of Laboratory and Clinical Medicine","volume":"147 2","pages":"Pages 103-104"},"PeriodicalIF":0.0,"publicationDate":"2006-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.lab.2006.01.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25839657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}